Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Small Intestinal Bacterial Overgrowth: early-phase trial registry

2 of 3 indexed Small Intestinal Bacterial Overgrowth trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Small Intestinal Bacterial Overgrowth: 3 US clinical trials tracked, 2 recruiting.

Small Intestinal Bacterial Overgrowth is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is US Department of Veterans Affairs, running 1 of these trials.

Enrollment posture brief

Registry condition small-intestinal-bacterial-overgrowth

OPEN 2 | RECR 67% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Small Intestinal Bacteri (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Small Intestinal Bacterial Overgrowth

Small Intestinal Bacterial Overgrowth lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Small Intestinal Bacterial Overgrowth on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Small Intestinal Bacterial Overgrowth is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Small Intestinal Bacterial Overgrowth records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CapScan collection capsule Device
1 trials
no intervention Other
1 trials
Rifaximin Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Small Intestinal Bacterial Overgrowth trials. A trial with sites in several states counts in each.

Utah 1 trials
Indiana 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Small Intestinal Bacterial Overgrowth page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Intestinal Bacterial Overgrowth condition card totals 3 registered trials; most-linked intervention CapScan collection capsule; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.